8月12日 - ** NeOnc Technologies（NTHI.O）股价在盘前交易中上涨12.4%，至4.89美元
** 这家处于临床阶段的脑癌药物开发商表示，其实验性脑癌疗法NEO100在一项针对复发性高级别胶质瘤的中期研究中达到了主要目标。复发性高级别胶质瘤是一种经治疗后复发的侵袭性脑肿瘤
** 该公司称，6个月无进展生存率为48.9%，高于该研究预先设定的标准治疗20%的基准
** 公司报告称，中位总生存期为26.1个月，6个月时患者生存率为86.7%
** 该公司表示未报告重大毒性反应，副作用主要为轻度
** 计划与美国食品药品监督管理局（FDA）举行B类会议，讨论在尚无获批靶向疗法的治疗背景下，潜在的注册途径
** 截至上一交易日收盘，该公司股价年内累计下跌约47%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.